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Omi is a mammalian serine protease that is localized in
the mitochondria and released to the cytoplasm in
response to apoptotic stimuli. Omi induces cell death in
a caspase-dependent manner by interacting with the X-
chromosome linked inhibitor of apoptosis protein, as well
as in a caspase-independent way that relies on its
proteolytic activity. Omi is synthesized as a precursor
polypeptide and is processed to an active serine protease
with a unique PDZ domain. PDZ domains recognize the
extreme carboxyl terminus of target proteins. Internal
peptides that are able to fold into a b-ﬁnger are also
reported to bind some PDZ domains. Using a modiﬁed
yeast two-hybrid system, PDZOmi mutants were isolated
by their ability to bind the carboxyl terminus of human
Myc oncoprotein in yeast as well as in mammalian cells.
One such PDZm domain (PDZ-M1), when transfected
into mammalian cells, was able to bind to endogenous
Myc protein and induce cell death. PDZ-M1-induced
apoptosis was entirely dependent on the presence of Myc
protein and was not observed when c-myc null ﬁbroblasts
were used. Our studies indicate that the PDZ domain of
Omi can provide a prototype that could easily be exploited
to target speciﬁcally and inactivate oncogenes by binding
to their unique carboxyl terminus.
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Introduction
Omi, also known as HtrA2, is a human serine protease
with extensive similarity to bacterial high-temperature
requirement A (HtrA) protease (Pallen and Wren, 1997;
Faccio et al., 2000b). Bacterial HtrAs act as chaperones
at normal temperatures and as proteases at elevated
temperatures to cleave and remove denatured or
damaged proteins allowing the survival of bacteria
following heat shock and other stress (Pallen and Wren,
1997). Omi was originally isolated through binding to
Mxi2, an alternatively spliced form of p38 stress-
activated kinase (SAPK) (Faccio et al., 2000a). It was
subsequently isolated independently as an interactor of
presenilin, a protein found mutated in some individuals
with Alzheimer’s disease (Gray et al., 2000). Omi is
expressed ubiquitously and the amount of protein
increases when cells are exposed to heat shock or
treated with tunicamycin (Gray et al., 2000). The
proteolytic activity of Omi is also regulated by cellular
stress including kidney ischemia/reperfusion (Faccio
et al., 2000b). Recent studies have identiﬁed Omi as a
mitochondrial protein that is released to the cytoplasm
following apoptotic stimuli (Suzuki et al., 2001; Hegde
et al., 2002; Martins et al., 2002; Verhagen et al., 2002).
In the cytoplasm, Omi interacts with X-chromosome
linked inhibitor of apoptosis protein and relieves its
inhibition of caspase-9 (Suzuki et al., 2001; Hegde et al.,
2002). In addition, Omi can promote apoptosis in a
caspase-independent mechanism through its ability to
function as a serine protease (Suzuki et al., 2001; Hegde
et al., 2002; Martins et al., 2002; Verhagen et al., 2002).
Omi belongs to a family of mammalian proteases
consisting of two members, the other being L56/HtrA1,
a serine protease that is overexpressed in osteoathritic
cartilage (Hu et al., 1998), which was also repressed in
ﬁbroblasts following SV40 infection (Zumbrunn and
Trueb, 1996). The similarity between both proteins is
restricted to the carboxy-terminus, which includes the
proteolytic domain and a PDZ motif, while the amino-
terminus of the two proteins is different (Faccio et al.,
2000b). Furthermore, while Omi is intracellular, L56/
HtrA1 is secreted (Hu et al., 1998; Faccio et al., 2000b).
Omi is made as a precursor protein and is processed
by the removal of 133 amino terminal amino acids to
produce the mature protein consisting of the catalytic
domain and a PDZ motif (Suzuki et al., 2001; Hegde
et al., 2002; Martins et al., 2002; Verhagen et al., 2002).
PDZ domains are protein modules deﬁned by a unique
sequence of 80–100 amino acids able to recognize
speciﬁc C-terminal sequences in target proteins (Saras
and Heldin, 1996; Songyang et al., 1997). They are
named after the three proteins where they were
originally found: postsynaptic density protein-95
(PSD-95) (Cho et al., 1992), Drosophila discs large
tumor suppressor (Dlg) (Woods and Bryant, 1991), and
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the tight junction protein (ZO-1) (Itoh et al., 1993). PDZ
proteins are commonly involved in assembling large
protein complexes into signaling networks; for a recent
review, see Sheng and Sala (2001). Known PDZ
domains are grouped into four classes based on their
binding speciﬁcity (Levchenko et al., 1997; Bezprozvan-
ny and Maximov, 2001; Vaccaro et al., 2001). The PDZ
domain of Omi (PDZOmi) is unique both in amino-acid
sequence as well as binding speciﬁcity. Figure 1a
compares the amino-acid sequence of PDZOmi with that
of the other known PDZ domains. The only known
interactor of PDZOmi is the Mxi2 protein, an alterna-
tively spliced form of SAPK (Faccio et al., 2000b).
PDZOmi binds the carboxy-terminus of Mxi2 protein
that is different from the consensus sequences recog-
nized by the other families of PDZ domains (Figure 1b).
To further investigate the structural characteristics of
the PDZOmi domain, its amino-acid sequence was
randomly mutated and mutant domains (PDZm) with
altered speciﬁcity were selected. The altered speciﬁcity in
this case deﬁnes the ability of PDZm domains to bind the
carboxy-terminus of the human c-Myc oncoprotein.
Myc protein plays a major role in cell growth,
differentiation, apoptosis and cell transformation
(Littlewood and Evan, 1990; Evan et al., 1994). There-
fore, interfering with its function could have a major
effect on the fate of cells. Through this screening, several
Myc-speciﬁc PDZm domains were isolated and char-
acterized. One such Myc-speciﬁc PDZ mutant (PDZ-
M1) was selected for further analysis. PDZ-M1, when
expressed in mammalian cells fused to a nuclear
localization signal (Kalderon et al., 1984), was able to
bind a truncated cytoplasmic form of Myc protein
(Myc282–439) and efﬁciently translocate it to the cell
nucleus. Furthermore, the PDZ-M1 domain colocalized
with endogenous Myc protein. This speciﬁc targeting of
Myc resulted in increased and signiﬁcant apoptosis of
the transiently transfected cells. Using c-myc null
ﬁbroblasts, we found the ability of PDZ-M1 domain
to induce apoptosis was entirely dependent on the
presence of Myc protein. In conclusion, our studies
deﬁne the PDZ of Omi, originally identiﬁed by its
similarity with other known PDZ domains, as a true
functional domain. Furthermore, this work clearly
shows that the basic structure of the PDZOmi is ﬂexible
and can be exploited to engineer PDZm domains with
predetermined speciﬁcity. These PDZm binding domains
can provide a novel way to target speciﬁcally oncogenes
such as Myc, in an attempt to control the fate of cells.
Designed PDZm domains linked together in tandem can
also provide a biological scaffold on which to assemble
speciﬁc multiprotein complexes (biological motors) that
can perform speciﬁc tasks within cells.
Results
Isolation of PDZm with altered specificity
A population of 7.5 105 random PDZm mutants was
constructed in the yeast pJG4-5 vector. The complexity
and heterogeneity of this library was veriﬁed by
sequencing several randomly isolated clones. This
library of mutant PDZ domains was screened using a
modiﬁed yeast two-hybrid system to isolate clones
encoding domains that could bind the Myc282–439
C-terminus. This screen yielded 21 possible interactors
and further analysis showed that 15 of these were true
positives. Their DNA sequence was determined and
grouped into six distinct families (Figure 2).
Characterization of the PDZm domains
To verify the selected PDZm domains interacted with the
C-terminus of Myc282–439 and not somewhere else on the
bait, a member from each family was tested for
interaction against the Myc282–437 bait lacking the last
three amino acids (Myc D3). Additionally, they were
tested against Mxi2 to determine if they had lost their
original speciﬁcity. The results of these experiments are
shown in Figure 3a. Figure 3b shows results from
experiments to test the speciﬁcity of PDZ-M1 using
other known members of the Myc network of proteins
including N-Myc, Max and Mxi1 proteins (Zervos et al.,
1993).
Liquid assays for b-galactosidase activity (Schneider
et al., 1996) were used to measure the strength of the
interaction between the bait and prey proteins for each
yeast clone (Table 1). The PDZ-M1 domain shows the
strongest and most speciﬁc interaction with Myc282–439
and has lost the ability to bind Mxi2. PDZ-M1 has two
amino-acid substitutions: G390-V, located between bB
and bC strands, and R408-W, present between the aA
and bD. PDZ-M5 with only one of the amino-acid
substitutions, G390-V, shows the same strong binding
with Myc282–439 bait seen with PDZ-M1, but, unlike
PDZ-M1, retains some of its binding ability for Mxi2.
PDZ-M6 has two amino-acid substitutions located in
the same positions as PDZ-M1 and one of them is the
same, R408-W, whereas the other introduces a different
amino acid, G390-S. PDZ-M6 binds strongly to
Myc282–439, but also interacts weakly with both Mxi2
and Myc D3. PDZ-M4 also has two amino-acid
substitutions: Q422-H found between bD and bE;
E458-G, which is the last amino acid of PDZOmi, and
shows weak binding with Myc282–439. PDZ-M3 has four
amino-acid substitutions: two of them are present in the
two positions, 390 and 408, also found in other families
(G390-V, R408-L), and the other two are in different
locations P381-L and V439-A. PDZ-M3 also shows
weak binding to Myc282–439. PDZ-M2 has ﬁve mutations
G390-V, L392-F, K395-T, T457-K, E458-N and
binds weakly to both Myc282–439 and Myc D3.
Interaction of PDZ-M1 with Myc282–439 in mammalian
cells
The PDZ-M1 domain that recognizes Myc282–439 was
cloned into pEGFP-C1 (Clontech) mammalian expres-
sion vector. This vector when transfected into mamma-
lian cells expresses the PDZ-M1 domain as a fusion to
the green ﬂuorescent protein (GFP). A nuclear localiza-
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Figure 1 (a) Sequence alignment of the different classes of known PDZ domains. Several members from each class are aligned to indicate the conservation of amino acids in particular
positions. Class I has the most members. Omi is shown together with L56/HtrA1 based on the high similarity of their respective PDZ domains. a-Helices are shown as cylinders; the amino
acids responsible for the secondary structures are highlighted in blue color. PSD95-3 (residues 309–393), PSD95-2 (residues 156–246), PSD95-1 (residues 61–151) are all from PSD95 (Cho
et al., 1992); DLG is the discs large repeat 3 (residues 482–566) (Woods and Bryant, 1991); hDLG is the human homolog of the Drosophila DLG (residues 460–546) (Lue et al., 1994);
ZO1 is repeat 2 of the tight junction protein (residues 408–491) (Willott et al., 1993); ZO2 is a homolog of ZO1 (residues 93–176) (Jesaitis and Goodenough, 1994); Sap97 is repeat 3 of a
novel pre-synaptic protein homologous to SAP90 and the Drosophila discs large tumor suppressor protein (residues 461–545) (Muller et al., 1995); Lin 2a is a member of the MAGUK
family of cell junction proteins (residues 542–628) (Hoskins et al., 1996); TorSyn is a torpedo syntrophin protein (residues 65–152) (Adams et al., 1993). hCASK binds to the heparan
sulfate proteoglycan syndecan-2 (Daniels et al., 1998); p55 is the palmitoylated erythrocyte membrane protein (residues 67–153) (Ruff et al., 1991). nNOS is nitric oxide synthase (residues
12–100) (Bredt et al., 1991; Rieﬂer et al., 2001). hINADL-3 is a human homolog to Drosophila INAD (Vaccaro et al., 2001). (b) Consensus carboxy-terminal sequences recognized by
different classes of PDZ domains. PDZOmi does not belong to any of the four known classes, but rather deﬁnes a new class of PDZ domains. A representative protein for each class of
























tion signal (NLS) (Kalderon et al., 1984) was also added
to target the PDZ-M1 fusion protein to the cell nucleus.
The Myc282–439 was instead cloned into the pDsRed1-C1
vector (Clontech), which fuses a red ﬂuorescent protein
(RFP) to the N-terminus of Myc282–439. HeLa cells were
transiently transfected with both of these constructs or
the parental vectors as control. After 24 h, the sub-
cellular localization of the ﬂuorescent fusion proteins
was observed using a confocal microscope. Figure 4,
panel a1 shows the localization of the GFP-NLS-PDZ-
M1 protein to be, as expected, exclusively nuclear. Panel
b1 shows the DsRed-Myc282–439 to be present in the
cytoplasm of the transfected cells. Although Myc is a
nuclear oncoprotein, the carboxy-terminal part of the
protein (Myc282–439) used as bait in our experiments
lacks the nuclear localization signals that are present in
the N-terminus of Myc (Stone et al., 1987). Panel c1
shows HeLa cells cotransfected with both constructs;
DsRed-Myc282–439 is now present in the cell nucleus
where it colocalized with the GFP-NLS-PDZ-M1.
Interaction of PDZ-M1 with endogenous full-length Myc
protein
GFP-PDZ-M1 and a speciﬁc anti-Myc antibody (Santa
Cruz Biotechnology) that binds to the amino terminus
of the Myc protein (aa 1–262) were used to detect
interaction between PDZ-M1 and endogenous Myc
protein. This antibody was selected because it cannot
interfere with any protein–protein interaction that
occurs at the carboxy-terminus of the protein. Figure 5,
panel b3 shows that PDZ-M1 colocalizes with endogen-
ous Myc protein in transiently transfected HeLa cells.
When the PDZOmi was used instead, only coincidental
co-localization was observed with endogenous Myc
protein (panel a3). The expression and stability of the
various fusion proteins was monitored by Western blot
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Figure 2 Alignment of the amino-acid sequence of six families of PDZm domains isolated for their ability to bind the C-terminus of
Myc. PDZm domains are aligned and their amino-acid sequences compared with the wild-type PDZ domain. Amino-acid substitutions
(indicated in red) that conferred altered speciﬁcity are clustered in two areas in the PDZ domain at positions 390 and 408. Amino-acids
involved in secondary structures are highlighted in gray: a denotes a-helix and b denotes b-strand
PDZ-M1
Control


















Figure 3 Yeast two-hybrid assay of different LexA-fusion
proteins (baits) with various PDZ domains (preys). Yeast colonies
were transformed with the indicated bait and prey; blue color
results from a positive protein–protein interaction, white colonies
indicate no interaction between bait and prey. The baits used in (a)
are the carboxy-terminus of Myc (aa 282–439), the full-length
Mxi2, and the carboxy-terminus of Myc lacking the last three
amino acids (Myc C-term D3). (b) Speciﬁc interaction of PDZ-M1
with Myc282–439, while no interaction was observed with N-myc236–
394, Max or Mxi-1 (Zervos et al., 1993)
Table 1 Speciﬁcity and binding strength of the different PDZ
domains for Myc282–439 and Mxi2 proteins
Prey Bait
Myc282–439 Mxi2 Myc D3
PDZ-M1 +++  
PDZ-M2 +  /+
PDZ-M3 ++  
PDZ-M4 +  
PDZ-M5 +++ /+ +
PDZ-M6 +++ /+ 
Semiquantitative representation of the strength and speciﬁcity of
binding between the different PDZm domains and their targets. Results
were compiled from several independent yeast experiments that
measured b-galactosidase activity (Schneider et al., 1996).
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The PDZ-M1 promotes apoptosis in mammalian cells
The carboxyl terminus of Myc is essential for its ability
to bind to the Max protein and for these heterodimers to
bind to DNA (Blackwood et al., 1992; Solomon et al.,
1993; Grandori et al., 1996). Therefore, overexpression
of the PDZ-M1 in transiently transfected cells might
interfere with the normal function of Myc. Flow
cytometry and annexin V probe (BD Biosciences) were
used to investigate whether HeLa cells expressing the
PDZ-M1 exhibited increased apoptosis. Figure 7 shows
11% of transfected cells with the EGFP vector alone
were annexin V positive. Increased apoptosis was
observed in cells transfected with the PDZ-M1, where
52% were annexin V positive. When the PDZOmi, which
does not bind to the Myc protein, was used only 21% of
the transfected cells were found to be annexin V positive
(Figure 7).
PDZ-M1-induced apoptosis depends entirely on the
presence of Myc protein
TGR-1, HO15.19. (myc /) and HO/myc3 (myc +/+)
cells (Mateyak et al., 1997) were transiently transfected
Figure 4 Nuclear translocation of RFP-Myc282–439 through its speciﬁc interaction with GFP-NLS-PDZ-M1. (a1) HeLa cells
transfected with GFP-NLS-PDZ-M1. This fusion protein is present exclusively in the cell nucleus because of the nuclear localization
signal. (b1) Same cells transfected with RFP-Myc282–439. As expected, Myc282–439 is cytoplasmic, since it lacks the amino terminus that
includes the nuclear localization signals. C1 shows HeLa cells cotransfected with RFP-Myc282–439 and GFP-NLS-PDZ-M1. The
RFP-Myc282–439 is now present in the nucleus where it colocalizes with the GFP-NLS-PDZ-M1. a2, b2 and c2 are Normasky
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Figure 5 Colocalization of GFP-PDZ-M1 and endogenous Myc protein. HeLa cells were transiently transfected with GFP-PDZOmi
(a) or GFP-PDZ-M1 (b) After transfection, the cells were ﬁxed and incubated with anti-Myc polyclonal antibody followed by PE-
conjugated anti-rabbit antibody and subsequently examined by confocal microscopy. Confocal images of HeLa cells transfected with
GFP-PDZOmi (a1) or GFP-PDZ-M1 (b1). The same HeLa cells stained red with a Myc-speciﬁc antibody (a2) and (b2). Merged
ﬂuorescent image from 1 and 2 showing extensive colocalization of GFP-PDZ-M1 and endogenous Myc (yellow color) (b3) or very
limited colocalization with the GFP-PDZOmi (a3). Normasky images of the cells are also shown (a4 and b4)






Figure 6 Expression and stability of EGFP-fusion proteins was
monitored by Western blot analysis. Equal amounts of whole-cell
lysates obtained 24 h post-transfection were subjected to SDS–
PAGE followed by Western blot analysis using anti-GFP mono-
clonal antibody as described in Materials and methods. Lane 1
shows prestained protein size markers, lanes 2 and 3 represent
lysates obtained after transfection of HeLa cells with EGFP-NLS-
PDZOmi and EGFP-NLS-PDZ-M1, including the NLS, lanes 4 and
5 show lysates obtained after transfection of HeLa cells with
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Figure 7 Expression of GFP-PDZ-M1 induces apoptosis in HeLa
cells. HeLa cells were transfected using the following constructs:
EGFP-C1 vector, EGFP-PDZOmi and EGFP-PDZ-M1. Transfected
cells were detached and stained with PE-conjugated annexin V. The
population of GFP-expressing cells that was also positive for
annexin V was analysed by FACSCalibur Flow cytometry. Bars
represent the percentage of GFP-expressing cells that were also
annexin V positive. The number shown below the abscissa is the
average of three independent experiments 7s.e.
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with EGFP-PDZ-M1, control vector or EGFP-PDZOmi
to investigate whether PDZ-M1 induced apoptosis
was dependent on the presence of Myc protein.
Flow cytometry and annexin V staining were
used to detect apoptosis in transfected cells.
Figure 8 shows PDZ-M1 can induce apoptosis in
28% of transfected parental TGR-1 cells that express
Myc. HO15.19 (myc/) cells were resistant to
PDZ-M1-induced apoptosis, only 12% of transfected
cells were apoptotic that is similar to cells trans-
fected with the control vector or with EGFP-PDZOmi.
When expression of Myc was reconstituted, these
cells again became susceptible to PDZ-M1-induced
apoptosis. The overall percentage of apoptotic
cells was higher for the HO/myc3 reconstituted
cells than the TGR-1 parental cell line independent
of the construct used in the transfections. Since
reconstitution of myc expression was achieved by
retroviral infection, HO/myc3 cells have higher levels
of Myc and its expression is not regulated as in the
parental TGR-1 cells (Mateyak et al., 1997). This
higher level of Myc did not affect the overall ratio of
apoptotic cells expressing PDZ-M1 apoptotic cells
expressing PDZOmi that was the same for both TGR-1
and HO/myc3 cell lines.
Discussion
Omi/HtrA2 is a serine protease isolated originally as an
interactor of Mxi2 kinase (Faccio et al., 2000b). The
mature Omi protein consists of a catalytic domain as
well as a PDZ motif. Its amino-acid sequence has been
conserved from bacteria to humans (Faccio et al.,
2000b). There is 36% identity and 58% similarity in
the amino-acid sequence between bacterial HtrA and
mature human Omi protein (Faccio et al., 2000b).
Bacterial HtrA is a chaperone at normal temperatures
and an active protease at elevated temperatures that can
cleave and remove denatured or damaged proteins
leading to the survival of bacteria (Spiess et al., 1999;
Krojer et al., 2002). There is also a mammalian homolog
of Omi called L56/HtrA1 (Zumbrunn and Trueb, 1996;
Hu et al., 1998), which has 52% identity and 72%
similarity with mature Omi. The highest similarity
between these two proteins is found in their catalytic
domains, which share 61% identity and 80% similarity.
There is less similarity in the PDZ domains of Omi and
L56/HtrA1, which share 40% identity and 62%
similarity. Bacterial HtrA has two PDZ domains that
are necessary for multimerization of the enzyme as well
as binding to its substrates (Fanning and Anderson,
1996; Hung and Sheng, 2001). The function of the single
PDZOmi is not known, although it is assumed, as with
other PDZ domains, that it is involved in protein–
protein interactions. Since Omi is a serine protease, its
PDZOmi domain might have a role in the recognition
and binding of potential substrates. Furthermore, there
is an alternatively spliced form of Omi/HtrA2 (D-Omi)
that is found only in kidney, colon and thyroid tissues
(Faccio et al., 2000c). D-Omi is an inactive protease, has
a modiﬁed PDZ domain and its physiological function
in these tissues is unknown (Faccio et al., 2000c).
Figure 1 shows an alignment of the amino-acid sequence
of the ﬁve classes of PDZ domains performed using the
Clustal W program (Aiyar, 2000). The secondary
characteristic elements deﬁning PDZ domains, derived
from X-ray crystallographic studies, are highlighted.
Secondary structure motifs of the PDZOmi were
predicted using homology modeling software and the
PDZ-3 of PSD-95 as a template. This comparison
reveals that the overall topology of the PDZ repeat is
strongly conserved in all ﬁve classes. The overall
structure of PDZOmi is similar to other known PDZ
domains. While it has six b-strands and two a-helices,
the so-called variable loop, located between putative
strands bB and bC, is slightly longer in PDZOmi than that
of the other classes of domains. As a result, the bD
strand appears distorted (Hung and Sheng, 2001).
Structural studies have shown the carboxy-
terminal peptide (ligand) ﬁts in the hydrophobic pocket
that includes the a-helix (aB), the second b-strand (bB),
as well as the conserved GLGF loop (Doyle et al., 1996).
This loop in PDZOmi is represented by a different
amino-acid sequence, LAEL. The PDZOmi also differs
from other families of PDZ domains, in that its variable
loop between bB and bC is longer and, as a result, the









Constructs TGR-1 HO15.19 HO/Myc3
EGFP-C1 10± 2 12± 3 19± 2
EGFP+PDZOmi 9± 1 10± 2 21± 3














Figure 8 Expression of GFP-PDZ-M1 induces apoptosis only in
the presence of Myc. TGR-1, HO15.19 (c-myc/) and HO/myc3
ﬁbroblasts were transfected using Lipofectamine 2000 (Life
Technologies) with the following constructs: EGFP-C1 vector,
EGFP-PDZOmi and EGFP-PDZ-M1. Transfected cells were
detached and stained with PE-conjugated annexin V. The popula-
tion of GFP-expressing cells that was also positive for annexin V
was analysed by FACSCalibur Flow cytometry. Each bar
represents the percentage of GFP-expressing cells that were also
annexin V positive. Different colors indicate the different plasmid
used for transfection. Results shown in the table are the average of
three independent experiments for each cell lines 7s.e.
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PDZOmi might have different binding speciﬁcity and it
could potentially deﬁne a new class of PDZ domains.
The PDZ domain of L56/HtrA1 is also included in class
V together with Omi. The binding speciﬁcity of L56/
HtrA1 is not known, but its PDZ domain has extensive
amino-acid sequence similarity with the PDZ domain of
Omi (Faccio et al., 2000b).
Mxi2 is the only known protein that speciﬁcally binds
the PDZ domain of Omi. Mxi2 is an alternatively spliced
form of SAPK and was used as bait in the original
isolation of Omi (Faccio et al., 2000b). The carboxy-
terminus of Mxi2 ends in DIELVMI amino-acid
sequence and deletion of the last two amino acids
completely abolish its binding with PDZOmi (Faccio
et al., 2000b). To investigate the structural character-
istics of the PDZOmi, its amino-acid sequence was
randomly mutated and the pool of mutants was
screened for a PDZm with altered binding speciﬁcity.
In this case, the pool was screened for the ability to bind
the carboxy-terminus of Myc (Myc282–439). Myc is a
nuclear oncoprotein involved in cell growth, apoptosis,
differentiation and cell transformation (Littlewood and
Evan, 1990; Evan et al., 1994). The carboxy-terminus of
Myc ends in the amino-acid sequence LRNSCA that is
substantially different from the Mxi2 carboxy-terminus
that ends in DIELVMI. Myc protein does not bind the
wild-type PDZOmi. Using a yeast two-hybrid screen, we
were able to obtain PDZm domains that could bind
Myc282–439. These PDZ
m domains were grouped into six
families based on their binding strength and speciﬁcity.
Some of them bound to Myc282–439 but also retained the
ability to bind weakly to Mxi2. Others bound to Myc282–
439 but also bound to the MycD3, indicating that they
recognized amino acids outside the extreme carboxy-
terminus of the Myc protein. Several PDZm proteins
showed strong and speciﬁc binding with Myc282–439.
When the amino-acid sequence of the different PDZm
was deduced, most of the mutations were found
clustered at positions 390 and 408 of the PDZ domain.
Amino acids in these two positions were invariably
changed to be hydrophobic. One family of PDZm (PDZ-
M1) that exhibited strong and speciﬁc binding with
Myc282–439 was selected for further investigation. This
family had a Gly390-Val and Arg408-Trp substitution
in its PDZ domain. Both amino-acid substitutions were
necessary for changing the speciﬁcity of the PDZOmi
because another PDZm family that only differed in a
single position, (Gly390-Val), showed binding to both
Myc and Mxi2. Furthermore, the ability of PDZ-M1 to
bind to the Myc282–439 bait protein in mammalian cells
was also investigated. Myc is a nuclear protein, but
Myc282–439 used in our experiments is cytoplasmic
because it lacks the nuclear localization signals that
are located in the amino terminus of the protein (Stone
et al., 1987). We therefore expressed the PDZ-M1
speciﬁc for Myc282–439 with a strong nuclear localization
sequence fused to the GFP. The Myc282–439 bait was also
expressed fused to the RFP. When both PDZ-M1 and
Myc282–439 were coexpressed in mammalian cells, PDZ-
M1 was able to bind to and translocate Myc282–439 to the
cell nucleus. Whether, the PDZ-M1 domain could also
bind to the endogenous Myc protein and interfere with
its normal function was further investigated. PDZ-M1
was expressed in transiently transfected mammalian
cells and found to colocalize with endogenous Myc
protein. Furthermore, the same cells transfected with
PDZ-M1 exhibited increased apoptosis compared with
cells transfected with a control PDZOmi, domain that
does not bind to Myc. To further establish that the
PDZ-M1-induced apoptosis is the result of a speciﬁc
interaction with endogenous Myc protein, we used
c-Myc deﬁcient ﬁbroblasts (HO15.19). These cells when
transfected with PDZ-M1 were resistant to apoptosis.
When c-myc expression was reconstituted in these cells
(HO/myc3) they reverted back to being sensitive to
PDZ-M1-induced apoptosis. These results clearly de-
monstrate that the ability of PDZ-M1 to induce
apoptosis is entirely dependent on its interaction with
Myc protein. Furthermore, PDZ-M1 by binding the
carboxyl terminus of Myc interferes with the normal
function of this protein driving cells to apoptosis. This is
the ﬁrst report of a PDZ domain used to target and
modify the activity of Myc protein.
Our data indicate that the PDZ domain of Omi can be
used as a prototype to develop artiﬁcial PDZ domains
able to target cellular proteins. In a similar approach,
the PDZ domain of the Ras-binding protein AF-6 was
used as a prototype to develop PDZ mutants able to
bind new protein targets (Schneider et al., 1999; Gee
et al., 2000). For successful interaction to occur, the
carboxy-terminus of the target proteins, recognized by
the PDZ domains, must be exposed and available for
binding. These artiﬁcial PDZ domains can provide
scaffolds for the development of speciﬁc multi-protein
complexes. They can easily be used to target, translo-
cate, inhibit or enhance the normal function of
numerous cellular proteins, thus providing information
on the normal function of proteins and their potential
role in human disease. Finally, artiﬁcial PDZ domains
can also be used as therapeutic agents to target and
modulate the activity of oncogenes such as the Myc
proto-oncogene used in the experiments reported here.
Materials and methods
Yeast two-hybrid experiments
EGY48 (MATa trp1 ura3 his3 LEU2::pLex Aop6-LEU2) was
used as the host yeast strain for all two-hybrid interaction
experiments (Gyuris et al., 1993). This yeast strain has both an
integrated LEU reporter gene with upstream LexA operators,
as well as a pSH18-34 (LexAop-lacZ) 2m plasmid that directs
the synthesis of b-galactosidase (Gyuris et al., 1993). Positive
protein–protein interactions between the bait and prey were
initially detected by the ability of the yeast to grow on GAL-
Ura-Trp-His-Leu-selective yeast plates. They were further
tested on Ura-His-Trp-X-gal plates. Plasmids were rescued
from positive clones and introduced into KC8 E. coli by
electroporation. DNA sequence was determined by sequencing
both DNA strands with a commercially available kit (PE
Applied Biosystems) using an ABI Prism 310 Genetic Analyzer
(Perkin–Elmer). The presence and stability of the recombinant
proteins in yeast cells was monitored by Western blot analysis
using either LexA (for baits) or HA-antibodies (for preys).
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Random mutations in the PDZOmi (between amino acids 335
and 458) were introduced using PCR reactions and the
following primers: Primer A (50-end): 50-GATGTCCCAGAT-
TATGCCTCTCCCGAATTCTCTGATCGTCTTCGAGAG
TTT-30. Primer B (30-end): 50-CTCTGGCGAAGAAGTCCA
AAGCTTCTCGAGTCATTCTGTGACCTCAGGGGT-30
A DNA polymerase was used that is prone to errors when
copying DNA (Mutazyme, Stratagene). To increase the
mutation frequency, four sequential PCR reactions were
performed, in which the product of the ﬁrst reaction was
diluted 1 : 1000 in TE buffer and used as the template for the
following reaction. All four PCR reactions were combined, the
DNA was digested withMfeI/XhoI and cloned into the EcoRI/
XhoI of the pJG4-5 vector (Fusco et al., 1999). This DNA was
used to transform yeast that already contained a bait
representing the C-terminus of Myc (aa 282–439) cloned in
the pL202 expression vector. A population of 7.5 105
independent yeast clones were screened as described (Zervos
et al., 1993).
Construction of c-MycD3 deletion mutants
The following primers were used in a PCR reaction: Primer C
(50-end): 50-CCGGAATTCCCTTCTGCTGGAGGC-30. Pri-
mer D (30-end): 50-GCGGGATCCTTAGTTCCGTAGCTGT
TC-30. Primer D introduces a stop codon (TAA) at position
1310 (aa 437) in the Myc sequence. This truncated form of
Myc lacks the last three C-terminal amino acids. After the
PCR, the DNA fragment was digested EcoRI/BamHI and
cloned into the corresponding sites of the pL202 yeast vector.
The speciﬁcity of the different PDZm domains against LexA-
MycD3aa, LexA-Mxi2 and LexA-Myc282–439 was determined
using standard yeast two-hybrid methodologies (Zervos et al.,
1993; Fusco et al., 1999).
Construction of LexA-N-myc, Max and Mxi1 baits
The following primers were used in a PCR reaction for cloning
of N-myc c-terminal (aa 236–394) and Max full length: Primer
E (N-myc 50-end): 50-CCGGAATTCGCCCTGGGTCCCGG-
GAGGGCT. Primer F (N-myc 30-end): 50-CGCGGATCC-
CTAGCAAGTCCGAGCGTGTTCAAT. Primer G (Max
50-end): 50-CCGGAATTCTATGAGCGATAACGATGACA
TC. Primer H (Max 30-end): 50- CGCGGATCCTTAGCTG-
GCCTCCATCCGGAG.
The PCR products were digested with EcoRI/BamHI and
cloned into the corresponding sites of the pL202 yeast bait
vector. LexA-Mxi1 has been previously described (Zervos
et al., 1993).
Mammalian expression of recombinant proteins
The following primers were used to PCR the DNA fragments
corresponding to wild-type PDZOmi and PDZ-M1 from yeast
vectors: Primer I (50-end): 50-CCGCTCGAGCGCCTC-
CAAAAAAGAAGAGAAAGGTAGCTT CTGATCGTCT-
TCGAGAGTTTC-30. Primer J (30-end): 50-CGGGGTACCT-
CATTCTGTGACCTCAGGGG-30. Primer I includes the
DNA sequence (underlined) that encodes the SV40 NLS,
PPKKKRKVA (Kalderon et al., 1984) in frame with the PDZ
domain. The PCR products were digested with XhoI/KpnI and
cloned in the corresponding sites of pEGFP-C1 vector
(Clontech).
The Myc C-terminus DNA sequence corresponding to
aa 282–439 was ampliﬁed using the following PCR primers:
Primer K (50-end): 50-CGGAATTCCCCTTCTGCTGGAG
GC-30. Primer L (30-end): 50-CCGGGATCCTTACGCACAA-
GAGTTC-30. The PCR product was digested with EcoRI/
BamHI and cloned in the corresponding sites of pDsRed1-C1
vector (Clontech).
In a different set of experiments, DNA corresponding to
wild-type PDZOmi or PDZ-M1 without the NLS was ampliﬁed
using the following primers: Primer M (50end) 50-
CGGAATTCTTCTGATCGTCTTCGAGAGTTTC-30. Pri-
mer N (30end) 50-CGGGGTACCTCATTCTGTGACCT-
CAGGGG-30. The PCR products were precipitated, digested
with EcoRI and KpnI, and cloned to the corresponding sites of
pEGFP-C1 vector (Clontech).
Cell lines and culture conditions
HeLa cells were grown using F12-Nutrient mixture (HAM)
media (Life Technologies) supplemented with 10% FCS
(Sigma), 2mm l-glutamine, 100U/ml penicillin and 100mg/
ml streptomycin (Life Technologies). TGR-1 (c-myc+/+),
HO15.19 (c-myc/ homozygous knockout) and HO/myc3
(HO15.19 cells infected with a retrovirus vector expressing c-
myc) were grown in DMEM (GIBCO) supplemented with
2mm L-glutamine, 100U/ml penicillin, 100mg/ml strepto-
mycin, 1mm sodium pyruvate (Sigma).
Transfections and immunofluorescence microscopy
For immunoﬂuorescence, the cells were grown on cover
slips. Approximately, 70% conﬂuent cells were transfected
with 2 mg of GFP-NLS-PDZOmi and RFP-Myc282–439 using
Lipofectamine Plus reagent according to the instructions
provided by the manufacturer (Life Technologies). After
24 h, the transfected cells were washed three times with
PBS and ﬁxed with 4% paraformaldehyde. The coverslips
were then placed on glass slides using Fluoromount-G
solution (Southern Biochemical Association). The subcellular
localization of GFP- and RFP-tagged proteins was monitored
using a LSM510 confocal laser-scanning microscope
(Carl Zeiss).
Western blot analysis
Transiently transfected cells were lysed using a Triton X-100
based lysis buffer (1% Triton X-100, 10% glycerol, 150mm
NaCl, 20mm tris pH 7.5, 2mm EDTA) in the presence
of a protease inhibitor mix (Roche). Approximately, 20mg
of whole-cell extracts were resuspended in SDS-sample
buffer and boiled for 3min. The samples were resolved
by SDS–polyacrylamide gel electrophoresis (PAGE) and
electro-transferred onto PVDF membranes (NEN Life
Science products) using a Semi-Dry cell Transfer Blot
(Bio-Rad). Nonfat dry milk (2%) in TBST buffer was used
to block nonspeciﬁc binding of the membrane. The membrane
was incubated with an anti-GFP monoclonal antibody
(Santa Cruz Biotechnology), 1 : 700 dilution, followed by a
secondary peroxidase-conjugated goat anti-mouse (Jackson
ImmunoResearch) 1 : 15000 dilution and visualized by ECL
(Pierce).
Flow cytometry
HeLa, TGR-1, HO15.19, HO/myc3 cells were grown in
six-well plates to 60% conﬂuence and were transfected
with EGFPC1 vector, GFP-PDZOmi or GFP-PDZ-M1
using Lipofectamine Plus Reagent according to the instruc-
tions provided by the manufacturer (Life Technologies).
Transfected cells were detached 48 h later using 0.02%
EDTA (Sigma), washed twice with ice-cold PBS, resuspended
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in 1X binding buffer (BD Bioscience), and stained
with PE-conjugated annexin V according to BD Bioscience
protocol. Analysis of annexin V, GFP positive cells was
performed on a FACS Vantage Flow Cytometer (Becton
Dickinson).
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